Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.

    ... of the spliceosomal mutations on RNA splicing and cell growth have been evaluated only in a limited context to date, however, and the ...

    Research Article last updated 10/22/2013 - 3:41pm.

  2. Revisiting use of growth factors in myelodysplastic syndromes

    ... with a high IPSS score. The advent of use of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and recombinant erythropoietin (EPO) has improved ...

    Research Article last updated 07/31/2012 - 12:57pm.

  3. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes

    ... that erlotinib has in vivo and in vitro off epidermal growth factor receptor (EGFR)-target activity in MDS. We conducted a phase II ...

    Research Article last updated 05/22/2014 - 10:33am.

  4. Paroxysmal Nocturnal Hemoglobinuria (PNH)

    ... of mature PNH red blood cells. Some doctors believe this growth happens because people with PNH have bone marrow that is weaker than ... Having aplastic anemia is the only known risk factor for developing PNH. More than 10 out of every 100 people with aplastic ...

    Page last updated 09/30/2017 - 11:34am.

  5. Myelodysplastic syndromes: therapy and outlook

    ... has been further enhanced with immunosuppressive agents, growth factor support, and biologic response modifiers. Initial treatment ...

    Research Article last updated 07/31/2012 - 1:27pm.

  6. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... causes hematological toxicity that is managed with growth factor support, blood transfusions, and dose and schedule adjustment. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 02/04/2014 - 1:37pm.

  8. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... to prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 07/31/2012 - 2:02pm.

  9. Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes

    ... our studies identify severe baseline neutropenia as a risk factor for infection-associated adverse events after induction chemotherapy and ... the rationale for the risk-adapted testing of myeloid growth factor support in this high-risk AML/MDS patient subset. ...

    Research Article last updated 01/07/2014 - 12:42pm.

  10. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... to prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 10/11/2011 - 5:58pm.